Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, Ann Arbor stage II, III, or IV Diffuse large B-cell lymphoma (DLBCL) according to the Revised European American Lymphoma(REAL)/World Health Organization (WHO) classification .~* Central pathology review confirming the DLBCL diagnosis and Cluster of differentiation 20 (CD20) positivity, and no evidence of DLBCL in bone marrow~* First-line treatment of DLBCL must have been 6 or 8 cycles of standard CHOP chemotherapy in combination with rituximab .~* Complete remission(CR) or unconfirmed complete remission(CRu) according to the International Workshop Response Criteria for Non Hodgkins Lymphoma (NHL) described by Cheson et al and modified for this study after first-line treatment with CHOP-R. Computerised Tomography (CT) scans of chest, abdomen, pelvis, and neck (if applicable) must have been performed within 6 weeks after the last dose of the last course of CHOP-R. Applicability of the neck CT means that the patient had involvement of the neck region by palpation / physical examination at first diagnosis (pre-CHOP-R).~* Central radiographic review of the CT scans from before and after first-line treatment with CHOP-R fulfilling the radiological requirements for CR/CRu~* Patients 60 years of age or older at time of randomization~* WHO performance status (PS) of 0 to 2 within 1 week of randomization~* Absolute neutrophil count greater than or equal to 1.5 x 10\^9/L within 1 week of randomization~* Hemoglobin greater than or equal to 10 g/dL within 1 week of randomization~* Platelets greater than or equal to 150 x 10\^9/L within 1 week of randomization~* Life expectancy of 3 months or longer~* Written informed consent obtained according to local guidelines~Exclusion Criteria:~* Presence of any other malignancy or history of prior malignancy except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma~* Prior radioimmunotherapy, radiation therapy, or any other NHL therapy except first-line CHOP-R~* Presence of gastric, central nervous system or testicular lymphoma at first diagnosis~* Histological transformation of low-grade non-Hodgkin's lymphoma (NHL)~* Known seropositivity for hepatitis C virus or hepatitis B surface antigen~* Known history of Human Immunodeficiency virus (HIV) infection~* Abnormal liver function: total bilirubin \> 1.5 x upper limit of normal (ULN) or Alanine Aminotransferase \> 2.5 x ULN within 1 week of randomization~* Abnormal renal function: serum creatinine \> 2.0 x ULN within 1 week of randomization~* Nonrecovery from the toxic effects of CHOP-R therapy~* Known hypersensitivity to murine or chimeric antibodies or proteins~* Granulocyte Colony Stimulating Factor (G-CSF) or Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) therapy within two weeks (or four weeks if pegylated) prior to screening laboratory sampling~* Concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes,congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study~* Male and female patients of child-bearing potential unwilling to practice effective contraception during the study and unwilling or unable to continue contraception for 12 months after their last dose of study treatment~* Female patients who are pregnant or are currently breastfeeding~* Treatment with investigational drugs less than 4 weeks before the planned Day 1 or nonrecovery from the toxic effects of such therapy~* Surgery less than 4 weeks before the planned Day 1 or nonrecovery from the side effects of such surgery~* Concurrent systemic corticosteroid use for any reason except as premedication in case of known or suspected allergies to contrast media or as premedication for potential side effects of rituximab treatment~* Unwillingness or inability to comply with the protocol

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zevalin (Type: EXPERIMENTAL): Patients received Zevalin.~Zevalin Therapeutic Regimen:~Day 1: Initial administration of 250 mg/m\^2 rituximab, followed immediately by administration of 185 MBq of \[111In\]-ibritumomab tiuxetan ,in centers where centers where biodistribution imaging or dosimetry had not been required, the first rituximab infusion was given alone.~- Day 7-9: Rituximab 250 mg/m\^2, followed immediately by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg given as a slow intravenous push over 10 minutes.~Two treatment days one week apart were followed by a 12-week safety period.
- Observational (Type: NO_INTERVENTION): Patients in this arm did not receive any reference therapy; they remained free of any anti-lymphoma therapy and were observed for relapse. This was non-interventional Stage consisting of a longterm follow-up period (until completion of a median observation period of 5 years).

Based on this trial design, predict the completion outcome and termination type (if applicable).